Abstract
Objective
To describe incidence and clinical characteristics of cases of Guillain-Barré syndrome (GBS) in the USA during 2009–2015, and characteristics of GBS cases with antecedent cytomegalovirus (CMV) infection among persons with employer-sponsored insurance.
Methods
We analyzed medical claims from IBM Watson MarketScan® databases. GBS patients were defined as enrollees with an inpatient claim with GBS as the principal diagnosis code, based on ICD-9 or ICD-10, and ≥ 1 claim for lumbar puncture or EMG/nerve conduction study. We assessed intensive care unit (ICU) hospitalization, intubation, dysautonomia, and death. We also assessed selected infectious illness within 60 days prior to the first GBS-coded inpatient claim.
Results
We identified 3486 GBS patients; annual incidence was 1.0–1.2/100,000 persons during 2009–2015. GBS incidence was higher in males (1.2/100,000) than in females (0.9/100,000) (p = 0.006) and increased with age, from 0.4/100,000 in persons 0–17 years old to 2.1/100,000 in persons ≥ 65 years old (p < 0.001). Half of GBS patients were hospitalized in the ICU, 8% were intubated, 2% developed dysautonomia, and 1% died. Half had a claim for antecedent illness, but only 125 (3.5%) had a claim for specific infectious pathogens. The mean age among 18 GBS patients with antecedent CMV infection was 39 years versus 47 years among those without antecedent CMV infection (p = 0.038).
Conclusions
Incidence of GBS using a large national claims database was comparable to that reported in the literature, but cases appeared to be less severe. Half of GBS patients reported prior infectious illness, but only a minority had a specific pathogen identified.
Similar content being viewed by others
References
Hughes RA, Cornblath DR (2005) Guillain-Barre syndrome. Lancet 366:1653–1666
Willison HJ, Jacobs BC, van Doorn PA (2016) Guillain-Barre syndrome. Lancet 388:717–727
Sejvar JJ, Baughman AL, Wise M, Morgan OW (2011) Population incidence of Guillain-Barre syndrome: a systematic review and meta-analysis. Neuroepidemiology 36:123–133
Counotte MJ, Egli-Gany D, Riesen M et al (2018) Zika virus infection as a cause of congenital brain abnormalities and Guillain-Barre syndrome: from systematic review to living systematic review. F1000Res 7:196
Beghi E, Kurland LT, Mulder DW, Wiederholt WC (1985) Guillain-Barre syndrome. Clinicoepidemiologic features and effect of influenza vaccine. Arch Neurol 42:1053–1057
Kaplan JE, Schonberger LB, Hurwitz ES, Katona P (1983) Guillain-Barre syndrome in the United States, 1978-1981: additional observations from the national surveillance system. Neurology 33:633–637
Shui IM, Rett MD, Weintraub E, Marcy M, Amato AA, Sheikh SI, Ho D, Lee GM, Yih WK, Vaccine Safety Datalink Research Team (2012) Guillain-Barre syndrome incidence in a large United States cohort (2000-2009). Neuroepidemiology 39:109–115
Halpin AL, Gu W, Wise ME, Sejvar JJ, Hoekstra RM, Mahon BE (2018) Post-Campylobacter Guillain Barre Syndrome in the USA: secondary analysis of surveillance data collected during the 2009-2010 novel Influenza A (H1N1) vaccination campaign. Epidemiol Infect 146:1740–1745
Orlikowski D, Porcher R, Sivadon-Tardy V, Quincampoix JC, Raphaël JC, Durand MC, Sharshar T, Roussi J, Caudie C, Annane D, Rozenberg F, Leruez-Ville M, Gaillard JL, Gault E (2011) Guillain-Barre syndrome following primary cytomegalovirus infection: a prospective cohort study. Clin Infect Dis 52:837–844
Quint JB. Health research data for the real world: the MarketScan databases. Truven Health Analytics White Paper. [online]. Available at: https://marketscan.truvenhealth.com/marketscanuniversity/publications/2015%20MarketScan%20white%20paper.pdf
Shoffstall AJ, Gaebler JA, Kreher NC, Niecko T, Douglas D, Strong TV, Miller JL, Stafford DE, Butler MG (2016) The high direct medical costs of Prader-Willi syndrome. J Pediatr 175:137–143
Burwen DR, Sandhu SK, MaCurdy TE, Kelman JA, Gibbs JM, Garcia B, Markatou M, Forshee RA, Izurieta HS, Ball R, Safety Surveillance Working Group (2012) Surveillance for Guillain-Barre syndrome after influenza vaccination among the Medicare population, 2009-2010. Am J Public Health 102:1921–1927
Inokuchi H, Yasunaga H, Nakahara Y, Horiguchi H, Ogata N, Fujitani J, Matsuda S, Fushimi K, Haga N (2014) Effect of rehabilitation on mortality of patients with Guillain-Barre syndrome: a propensity-matched analysis using nationwide database. Eur J Phys Rehab Med 50:439–446
Salinas JL, Major CG, Pastula DM, Dirlikov E, Styczynski A, Luciano CA, Wojna V, Sharp TM, Sejvar JJ, Rivera-Garcia B (2017) Incidence and clinical characteristics of Guillain-Barre syndrome before the introduction of Zika virus in Puerto Rico. J Neurol Sci 377:102–106
McGrogan A, Madle GC, Seaman HE, de Vries CS (2009) The epidemiology of Guillain-Barre syndrome worldwide. A systematic literature review. Neuroepidemiology 32:150–163
Hafsteinsdottir B, Olafsson E, Jakobsson F (2018) Incidence and outcome of Guillain-Barre syndrome in Iceland: a population-based study. Acta Neurol Scand 138:454–458
Al-Hakem H, Sindrup SH, Andersen H et al (2018) Guillain-Barre syndrome in Denmark: a population-based study on epidemiology, diagnosis and clinical severity. J Neurol
Styczynski AR, Malta J, Krow-Lucal ER et al (2017) Increased rates of Guillain-Barre syndrome associated with Zika virus outbreak in the Salvador metropolitan area, Brazil. PLoS Negl Trop Dis 11:e0005869
Hughes RA, Rees JH (1997) Clinical and epidemiologic features of Guillain-Barre syndrome. J Infect Dis 176(Suppl 2):S92–S98
Granieri E, Andreasi NG, De Martin P et al (2019) Incidence study of Guillain-Barre syndrome in the province of Ferrara, Northern Italy, between 2003 and 2017. A 40-year follow-up. Neurol Sci 40:603–609
Prevots DR, Sutter RW (1997) Assessment of Guillain-Barre syndrome mortality and morbidity in the United States: implications for acute flaccid paralysis surveillance. J Infect Dis 175 Suppl 1:S151–S155
Flachenecker P (2007) Autonomic dysfunction in Guillain-Barre syndrome and multiple sclerosis. J Neurol 254 Suppl 2:Ii96–I101
Pfeiffer G, Schiller B, Kruse J, Netzer J (1999) Indicators of dysautonomia in severe Guillain-Barre syndrome. J Neurol 246:1015–1022
Winer JB, Hughes RA, Anderson MJ, Jones DM, Kangro H, Watkins RP (1988) A prospective study of acute idiopathic neuropathy. II. Antecedent events. J Neurol Neurosurg Psychiatry 51:613–618
Hughes RA, Hadden RD, Gregson NA, Smith KJ (1999) Pathogenesis of Guillain-Barre syndrome. J Neuroimmunol 100:74–97
Visser LH, van der Meche FG, Meulstee J et al (1996) Cytomegalovirus infection and Guillain-Barre syndrome: the clinical, electrophysiologic, and prognostic features. Dutch Guillain-Barre Study Group. Neurology 47:668–673
Stagno SBW (2006) Cytomegalovirus. In: Remington JS, Klein JO, Wilson CB, Baker CJ (eds) Infectious disease of the fetus and newborn infant. WB Saunders Co, Philadelphia, pp 389–424
Bogliun G, Beghi E (2002) Validity of hospital discharge diagnoses for public health surveillance of the Guillain-Barre syndrome. Neurol Sci 23:113–117
Koobatian TJ, Birkhead GS, Schramm MM, Vogt RL (1991) The use of hospital discharge data for public health surveillance of Guillain-Barre syndrome. Ann Neurol 30:618–621
Sejvar JJ, Kohl KS, Gidudu J, Amato A, Bakshi N, Baxter R, Burwen DR, Cornblath DR, Cleerbout J, Edwards KM, Heininger U, Hughes R, Khuri-Bulos N, Korinthenberg R, Law BJ, Munro U, Maltezou HC, Nell P, Oleske J, Sparks R, Velentgas P, Vermeer P, Wiznitzer M, Brighton Collaboration GBS Working Group (2011) Guillain-Barre syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 29:599–612
Acknowledgments
We thank Mary Ann Hall for her editorial assistance and thoughtful review of the paper.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
This analysis only included deidentified data; it was therefore deemed by the Centers for Disease Control and Prevention (CDC) not to be human subject research and it did not require CDC’s Institutional Review Board approval.
Conflict of interest
The authors declare that they have no conflict of interest.
Financial support
This project did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Disclaimer
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention, US Department of Health and Human Services.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
ESM 1
(DOCX 24 kb)
Rights and permissions
About this article
Cite this article
Leung, J., Sejvar, J.J., Soares, J. et al. Guillain-Barré syndrome and antecedent cytomegalovirus infection, USA 2009–2015. Neurol Sci 41, 885–891 (2020). https://doi.org/10.1007/s10072-019-04156-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-019-04156-z